The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study

Authors

  • Lina U. Ivert Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden
  • Axel Svedbom 1Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet
  • Maria Lundqvist Department of Dermatology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
  • Carl-Fredrik Wahlgren Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet
  • Maria Bradley Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet. Department of Dermatology, Karolinska University Hospital
  • Emma K. Johansson

DOI:

https://doi.org/10.2340/actadv.v102.803

Keywords:

Atopic dermatitis, atopic eczema, depression, suicidal ideation, drug therapy, epidemiology

Abstract

Information on depressive symptoms among patients with atopic dermatitis (AD) undergoing systemic treatment in a real-world setting is scarce. This prospective real-world clinical cohort study analysed data from SwedAD, a Swedish national register comprising patients with AD undergoing systemic treatment. Data were collected at baseline (n = 120) and at follow-up at 6 months (range 3–9 months, n = 59), and 12 months (10 months or later, n = 36). Depression was assessed with the Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S) and AD with the Eczema Area Severity Index, the Patient-Oriented Eczema Measure, the Dermatology Life Quality Index and evaluation of pruritus. More than half of patients with moderate-to-severe AD had depressive symptoms at baseline, 24% presented with moderate-to-severe depression and 3% had pronounced suicidal ideation. Systemic treatment of AD significantly reduced both depression and AD symptoms at 6 months, and this positive effect remained at 12 months. In conclusion, depressive symptoms are common among adults with moderate-to-severe AD. Systemic treatment of AD significantly reduced depressive symptoms in parallel with AD symptoms.

Downloads

Download data is not yet available.

References

Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: adv00160.

https://doi.org/10.2340/00015555-3510

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1.

https://doi.org/10.1038/s41572-018-0001-z

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345-460.

https://doi.org/10.1016/S0140-6736(20)31286-1

Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017; 137: 26-30.

https://doi.org/10.1016/j.jid.2016.07.012

Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 178-187.

https://doi.org/10.1001/jamadermatol.2018.4566

Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456.e30.

https://doi.org/10.1016/j.jaad.2018.03.017

Patel KR, Immaneni S, Singam V, Rastogi S, Silverberg JI. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 402-410.

https://doi.org/10.1016/j.jaad.2018.08.063

Nicholas MN, Drucker AM. Depression and anxiety in atopic dermatitis: increasing recognition and opportunities to intervene. Br J Dermatol 2019; 181: 442-443.

https://doi.org/10.1111/bjd.18252

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.

https://doi.org/10.1111/jdv.14888

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 139-147.

https://doi.org/10.1016/j.jaad.2020.08.051

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.

https://doi.org/10.1056/NEJMoa1610020

Swedish quality register of Atopic Dermatitis (SwedAD). Svenskt kvalitetsregister för atopisk dermatit (Swedish) [updated 2021 Mar 15]. [Accessed 2021 Mar 23] Available from https://swedad.nu/vardgivare/om-swedad/.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.

https://doi.org/10.1192/bjp.134.4.382

Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 1994; 89: 21-28.

https://doi.org/10.1111/j.1600-0447.1994.tb01480.x

Wikberg C, Pettersson A, Westman J, Björkelund C, Petersson EL. Patients' perspectives on the use of the Montgomery-Asberg depression rating scale self-assessment version in primary care. Scand J Prim Health Care 2016; 34: 434-442.

https://doi.org/10.1080/02813432.2016.1248635

Svanborg P, Ekselius L. Self-assessment of DSM-IV criteria for major depression in psychiatric out- and inpatients. Nord J Psychiatry 2003; 57: 291-296.

https://doi.org/10.1080/08039480307281

Mattsson S, Olsson EMG, Carlsson M, Johansson BBK. Identification of anxiety and depression symptoms in patients with cancer: comparison between short and long web-based questionnaires. J Med Internet Res 2019; 21: e11387.

https://doi.org/10.2196/11387

Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry 1986; 148: 599-601.

https://doi.org/10.1192/bjp.148.5.599

Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 2020; 45: 606-612.

https://doi.org/10.1038/s41386-019-0570-x

Grinich EE, Schmitt J, Kuster D, Spuls PI, Williams HC, Chalmers JR, et al. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. Br J Dermatol 2018; 179: 540-541.

https://doi.org/10.1111/bjd.16732

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.

https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.

https://doi.org/10.2340/00015555-1246

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.

https://doi.org/10.1111/bjd.17744

Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol 2021; 185: 139-146.

https://doi.org/10.1111/bjd.19751

Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 2020; 9: 791.

https://doi.org/10.3390/jcm9030791

Bender BG, Ballard R, Canono B, Murphy JR, Leung DY. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol 2008; 58: 415-420.

https://doi.org/10.1016/j.jaad.2007.10.010

Jeon C, Yan D, Nakamura M, Sekhon S, Bhutani T, Berger T, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther (Heidelb) 2017; 7: 349-364.

https://doi.org/10.1007/s13555-017-0192-3

Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med 2019; 23: 2324-2332.

https://doi.org/10.1111/jcmm.14170

Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.

https://doi.org/10.1111/jdv.15634

Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom 2001; 70: 6-16.

https://doi.org/10.1159/000056219

Nicholas MN, Gooderham MJ. Atopic dermatitis, depression, and suicidality. J Cutan Med Surg 2017; 21: 237-242.

https://doi.org/10.1177/1203475416685078

Johansson R, Carlbring P, Heedman Å, Paxling B, Andersson G. Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life. PeerJ 2013; 1: e98.

https://doi.org/10.7717/peerj.98

Thyssen JP, Hamann CR, Linneberg A, Dantoft TM, Skov L, Gislason GH, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73: 214-220.

https://doi.org/10.1111/all.13231

Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin 2016; 32: 1645-1651.

https://doi.org/10.1080/03007995.2016.1195733

Dieris-Hirche J, Gieler U, Petrak F, Milch W, Te Wildt B, Dieris B, et al. Suicidal ideation in adult patients with atopic dermatitis: a german cross-sectional study. Acta Derm Venereol 2017; 97: 1189-1195.

https://doi.org/10.2340/00015555-2741

Malhi GS, Mann JJ. Depression. Lancet 2018; 392: 2299-2312.

https://doi.org/10.1016/S0140-6736(18)31948-2

Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J Dermatol 2015; 60: 211.

Wikberg C, Nejati S, Larsson ME, Petersson EL, Westman J, Ariai N, et al. Comparison between the Montgomery-Asberg Depression Rating Scale-Self and the Beck Depression Inventory II in primary care. Prim Care Companion CNS Disord 2015; 17: 10.4088/PCC.

https://doi.org/10.4088/PCC.14m01758

Downloads

Published

2022-10-24

How to Cite

Ivert, L. U., Svedbom, A., Lundqvist, M., Wahlgren, C.-F., Bradley, M., & Johansson, E. K. (2022). The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study. Acta Dermato-Venereologica, 102, adv00801. https://doi.org/10.2340/actadv.v102.803

Issue

Section

Articles

Categories